Drug Profile
JNJ 26528398
Alternative Names: JNJ-26528398Latest Information Update: 22 May 2014
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 30 Apr 2014 No development reported - Phase-I for Inflammation (in volunteers) in Belgium (PO)
- 30 Nov 2011 Phase-I clinical trials in Inflammation (in volunteers) in Belgium (PO)